NL-OMON29641已完成不适用
A randomized, controlled, open-label, parallel-arm, multi-centre intervention trial on the effect of a nutrient dense infant formula compared to current practice, on the growth and tolerance of infants in Spain.
umico Research B.V.0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Infants aged 0 to 9 months;
- •2. Infants with increased energy requirements and/or fluid restrictions and/or with indication for using high-energy feeds;
排除标准
- •1. Infants with cow's milk intolerance, major gastrointestinal hepatic or renal dysfunction, or inherited metabolic disorders including galactosaemia are excluded for this study;
- •2. Investigator's uncertainty about the willingness or ability of the caretaker to comply with the protocol requirements;
研究者
相似试验
已完成
4 期
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)Urea Cycle DisorderNCT03335488Amgen16
尚未招募
3 期
Study of Iron supplement in anemic pregnant women.CTRI/2024/06/069166Generex Pharmassist Pvt. Ltd.
进行中（未招募）
1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-DEFerring Pharmaceuticals A/S240
进行中（未招募）
1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1Level: PTClassification code 10060862Term: Prostate cancerProstate CancerEUCTR2008-005232-33-FRFerring Pharmaceuticals A/S240
进行中（未招募）
1 期
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent) - FE200486 CS30MedDRA version: 9.1 Level: PT Classification code 10060862 Term: Prostate cancerProstate CancerEUCTR2008-005232-33-GBFerring Pharmaceuticals A/S240